Key result
Rivaroxaban and apixaban showed no significant differences in trough (52.4 vs 76.0 ng/ml; P=0.12) or peak (187.2 vs 151.5 ng/ml; P=0.27) anti-Xa activity in NV-AF patients with high bleeding risk.
Why the study?
Does anti-Xa activity differ between rivaroxaban and apixaban in patients with NV-AF and a high risk of bleeding?
Population
41 patients with nonvalvular atrial fibrillation (NV-AF) and a higher risk of bleeding (HAS-BLED score ≥ 3)
Comparison
Oral factor Xa inhibitors vs Rivaroxaban vs. apixaban
Design
Cohort
Authors
Loading...
Does not support routine anti-Xa monitoring in high-bleeding-risk NV-AF; hypothesis-generating pilot data requires validation in larger trials.
Observational (n=41)
No
Does anti-Xa activity differ between rivaroxaban and apixaban in patients with NV-AF and a high risk of bleeding?
Absolute Event Rate: 52.4% vs 76%
p-value: p=0.12
In patients with NV-AF and high bleeding risk, trough and peak anti-Xa activity did not differ significantly between those treated with rivaroxaban versus apixaban.
Samoš et al. (2018) conducted an observational in Nonvalvular atrial fibrillation with high bleeding risk (n=41). Rivaroxaban vs. Apixaban was evaluated on Trough anti-Xa activity (p=0.12). Rivaroxaban and apixaban showed no significant differences in trough (52.4 vs 76.0 ng/ml; P=0.12) or peak (187.2 vs 151.5 ng/ml; P=0.27) anti-Xa activity in NV-AF patients with high bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: